Clover Health Investments Corp (CLOV)
Official siteHEALTHCARE • HEALTHCARE PLANS • NASDAQ
Market Cap: $2.65B
Last updated: Nov 17, 2026 at 4:34 PM ET
Clover Health Investments Corp (CLOV) Statistics
Clover Health Investments (CLOV) has a market cap of $2.65B and an enterprise value of $2.38B. Revenue grew 54.50% over the last 12 months from the 12 months before. Its share count is up 3.68% from a year earlier.
Total Valuation
Enterprise value is 10.11% below the market cap, as cash exceeds debt.
| Market Cap | $2.65B |
|---|---|
| Enterprise Value | $2.38B |
| Latest price (Nov 17, 2026) | $4.73 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.9x and 6.4x.
| P/E Ratio | 118.3x |
|---|---|
| Forward P/E | 80.0x |
| P/S Ratio | 0.9x |
| Forward P/S | 0.9x |
| P/B Ratio | 6.4x |
| P/TBV Ratio | 6.5x |
| P/FCF Ratio | 19.0x |
| P/OCF Ratio | 19.6x |
Enterprise Valuation
Counting debt and cash, the company is valued at 176.2x EBITDA and 17.0x free cash flow.
| EV / Earnings | 191.3x |
|---|---|
| EV / Sales | 0.9x |
| EV / EBITDA | 176.2x |
| EV / EBIT | 191.3x |
| EV / FCF | 17.0x |
Price Statistics
The stock is up 91.50% over 52 weeks and trades 2.16% above its 50-day average.
| Beta (1Y) | 1.13 |
|---|---|
| 52-Week Change | +91.50% |
| 1-Month Change | +6.53% |
| 3-Month Change | +12.09% |
| 6-Month Change | +35.14% |
| 5-Year Change | -40.53% |
| Total Return (1Y) | +91.50% |
| Total Return (3Y CAGR) | +66.74% |
| Total Return (5Y CAGR) | -3.36% |
| Return vs SPY (1Y) | +89.72% |
| Max Drawdown (1Y) | -39.50% |
| Max Drawdown (3Y) | -64.73% |
| Sharpe Ratio (1Y) | 1.21 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $4.63 |
| 200-Day Average | $3.68 |
| 52-Week Range | $1.58 to $5.59 |
| RSI (14 Days) | 50.8 |
| Average Volume (20 Days) | 4.65M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Returns and Efficiency
Return on equity is 3.19% over the last 12 months, against a 5-year average of -63.95%.
| Return on Equity (ROE) | 3.19% |
|---|---|
| Return on Assets (ROA) | 1.65% |
| ROE (5Y Average) | -63.95% |
| ROA (5Y Average) | -32.88% |
| ROIC (5Y Average) | -51.94% |
| Asset Turnover | 4.17x |
Scores
CLOV has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $2.74B over the last 12 months.
| Revenue | $2.74B |
|---|---|
| Revenue Growth (YoY) | +54.50% |
| Pretax Income | $12.45M |
| Net Income | $12.45M |
| EBITDA | $12.75M |
| EBIT | $12.45M |
| Reported EPS (TTM) | $0.04 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 51.86% of the $753.68M in total assets.
| Cash and Equivalents | $268.07M |
|---|---|
| Total Debt | $0 |
| Net Cash | $268.07M |
| Net Cash Per Share | $0.50 |
| Shareholder Equity | $390.87M |
| Book Value Per Share | $0.74 |
| Tangible Book Value | $387.88M |
| Tangible Book Per Share | $0.73 |
| Total Assets | $753.68M |
| Total Liabilities | $362.81M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $3.03M of capital spending, operating cash flow left $132.28M of free cash flow.
| Operating Cash Flow | $135.31M |
|---|---|
| Capital Expenditures | $3.03M |
| Free Cash Flow | $132.28M |
| FCF Per Share | $0.30 |
| Depreciation and Amortization | $459.00K |
Trailing 12 months through Sep 30, 2026.
Margins
| Pretax Margin | 0.45% |
|---|---|
| Net Margin | 0.45% |
| EBITDA Margin | 0.47% |
| EBIT Margin | 0.45% |
| FCF Margin | 4.83% |
| Gross Margin (5Y Average) | 13.89% |
| Operating Margin (5Y Average) | -18.69% |
| Net Margin (5Y Average) | -19.06% |
Growth
Revenue grew 20.28% a year over 3 years.
| Revenue Growth (3Y CAGR) | +20.28% |
|---|---|
| Revenue Growth (5Y CAGR) | +21.37% |
| Book Value Per Share Growth (2Y CAGR) | +0.18% |
| Tangible Book Per Share Growth (2Y CAGR) | +0.22% |
Dividends and Yields
CLOV does not pay a dividend. Its free cash flow yield is 5.26%.
| Earnings Yield | 0.85% |
|---|---|
| FCF Yield | 5.26% |
| Buyback Yield | -0.18% |
| Shareholder Yield | -0.18% |
Peer Position
Against 12 similar companies, CLOV has the highest P/E and the 6th highest P/S.
P/E RatioPeer median 28.5x
P/S RatioPeer median 0.6x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +6.16%
| P/E Ratio | 118.3x vs 28.5x median |
|---|---|
| P/S Ratio | 0.9x vs 0.6x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +54.50% vs +6.16% median |
Analyst Forecast
Consensus estimates put revenue growth at 37.99% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +37.99% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CLOV
What is CLOV's market cap?
Clover Health Investments has a market cap of $2.65B. Its enterprise value, which adds debt and subtracts cash, is $2.38B.
What is CLOV's P/E ratio?
Clover Health Investments has a trailing P/E ratio of 118.3x and a forward P/E of 80.0x.
How many shares of CLOV are outstanding?
Clover Health Investments has 531.60M shares outstanding. The count is up 3.68% from a year earlier.
Does CLOV pay a dividend?
No. Clover Health Investments does not pay a dividend.
How much debt does CLOV have?
Clover Health Investments has $0 of total debt and $268.07M of cash and equivalents, a net cash position of $268.07M.
CLOV pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors